Compare Amphastar Pharmaceuticals Inc (AMPH) vs HubSpot Inc (HUBS) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs HubSpot Inc — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while HubSpot Inc trades at $209.13 (market cap $10.62B). The key difference: HubSpot Inc is far larger — about 12.9× Amphastar Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| AMPH | HUBS | |
|---|---|---|
Market Cap | $826.08M | $10.62B |
Sector | Health | Technology |
52-Week High | $30.81 | $560.90 |
52-Week Low | $16.87 | $170.39 |
Enterprise Value | $1.22B | $9.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
HubSpot (HUBS) trades at $207.48, up 0.74% on the day, showing bullish momentum with strong technical support at $200 and resistance at $213. The company demonstrates robust revenue growth, reaching $3.13 billion in 2025, and has consistently beaten earnings expectations. Analyst sentiment is overwhelmingly positive with an 80.85% buy rating and a consensus price target of $273.53, indicating significant upside potential from current levels.
The outlook for HUBS remains favorable due to accelerating AI integration and customer growth, though high valuation multiples (P/E of 109.2) pose risks if growth slows. Competitive pressures in the CRM space and macroeconomic headwinds could challenge future performance, but strong cash flow generation and expanding margins support a bullish case for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About HubSpot Inc
HubSpot provides a cloud-based marketing, sales, and customer service software platform referred to as the growth platform. The applications are available ala carte or packaged together. HubSpot's mission is to help companies grow better and has expanded from its initial focus on inbound marketing to embrace marketing, sales, and service more broadly. The company was founded in 2006, completed its initial public offering in 2014, and is headquartered in Cambridge, Massachusetts.
Read more on HUBS →
